Abstract
In this study, we describe the successful use of a gene transfer approach to demonstrate the ability of forced BCR-ABL expression to deregulate the growth and differentiation of primitive naïve human hematopoietic cells after their transplantation into immunodeficient mice. Human CD34+ cord blood cells were exposed to an MSCV retrovirus containing a BCR-ABL-IRES-GFP (P210) cassette and then injected immediately into sublethally irradiated nonobese diabetic-severe combined immunodeficiency (NOD/SCID) or NOD/SCID-β2microglobulin−/− mice. P210- and control-transduced (GFP+) human hematopoietic cells were produced in the bone marrow of the mice at similar levels until termination of the experiments 5–6 months later. However, the P210-transduced cells produced a markedly different spectrum of progeny, with an increased ratio of myeloid to B-lymphoid cells and a frequently prolonged increase in erythroid and megakaryocytic cells. After 5 months, several of the mice transplanted with P210-transduced cells developed an increased WBC count and/or splenomegaly due to an expansion of the human GFP+ population. These findings demonstrate that forced expression of BCR-ABL in primitive transplantable human hematopoietic cells is sufficient to cause a rapid and persistent deregulation of their growth and differentiation in vivo with occasional evidence after several months of progression to an early stage of disease.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Groffen J, Stephenson JR, Heisterkamp N, De Klein A, Bartram CR, Grosveld G . Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22. Cell 1984; 36: 93–99.
Shtivelman E, Lifshitz B, Gale RP, Canaani E . Fused transcript of abl and bcr genes in chronic myelogenous leukaemia. Nature 1985; 315: 550–554.
Ben-Neriah Y, Daley GQ, Mes-Masson AM, Witte ON, Baltimore D . The chronic myelogenous leukemia-specific P210 protein is the product of the bcr/abl hybrid gene. Science 1986; 233: 212–214.
Konopka JB, Witte ON . Detection of c-abl tyrosine kinase activity in vitro permits direct comparison of normal and altered abl gene products. Mol Cell Biol 1985; 5: 3116–3123.
Van Etten RA, Jackson P, Baltimore D . The mouse type IV c-abl gene product is a nuclear protein, and activation of transforming ability is associated with cytoplasmic localization. Cell 1989; 58: 669–678.
Van Etten RA . Retroviral transduction models of Ph+ leukemia: advantages and limitations for modeling human hematological malignancies in mice. Blood Cells Mol Dis 2001; 27: 201–205.
Glimm H, Eisterer W, Lee K, Cashman J, Holyoake TL, Nicolini F et al. Previously undetected human hematopoietic cell populations with short-term repopulating activity selectively engraft NOD/SCID-β2 microglobulin-null mice. J Clin Invest 2001; 107: 199–206.
Kinsella TM, Nolan GP . Episomal vectors rapidly and stably produce high-titer recombinant retrovirus. Hum Gene Ther 1996; 7: 1405–1413.
Chalandon Y, Jiang X, Hazelwood G, Loutet S, Conneally E, Eaves A et al. Modulation of p210BCR-ABL activity in transduced primary human hematopoietic cells controls lineage reprogramming. Blood 2002; 99: 3197–3204.
Hennemann B, Conneally E, Pawliuk R, Leboulch P, Rose-John S, Reid D et al. Optimization of retroviral-mediated gene transfer to human NOD/SCID mouse repopulating cord blood cells through a systematic analysis of protocol variables. Exp Hematol 1999; 27: 817–825.
Jiang X, Lopez A, Holyoake T, Eaves A, Eaves C . Autocrine production and action of IL-3 and granulocyte colony-stimulating factor in chronic myeloid leukemia. Proc Natl Acad Sci USA 1999; 96: 12804–12809.
Christianson SW, Greiner DL, Hesselton R, Leif JH, Wagar EJ, Schweitzer IB et al. Enhanced human CD4+ T cell engraftment in β2-microglobulin-deficient NOD-scid mice. J Immunol 1997; 158: 3578–3586.
Jiang X, Ng E, Yip C, Eisterer W, Chalandon Y, Stuible M et al. Primitive interleukin 3 null hematopoietic cells transduced with BCR-ABL show accelerated loss after culture of factor-independence in vitro and leukemogenic activity in vivo. Blood 2002; 100: 3731–3740.
Conneally E, Cashman J, Petzer A, Eaves C . Expansion in vitro of transplantable human cord blood stem cells demonstrated using a quantitative assay of their lympho-myeloid repopulating activity in nonobese diabetic-scid/scid mice. Proc Natl Acad Sci USA 1997; 94: 9836–9841.
Bhatia M, Wang JCY, Kapp U, Bonnet D, Dick JE . Purification of primitive human hematopoietic cells capable of repopulating immune-deficient mice. Proc Natl Acad Sci USA 1997; 94: 5320–5325.
Raskind WH, Fialkow PJ . The use of cell markers in the study of human hematopoietic neoplasia. Adv Cancer Res 1987; 49: 127–167.
Verstegen MMA, Cornelissen JJ, Terpstra W, Wagemaker G, Wognum AW . Multilineage outgrowth of both malignant and normal hemopoietic progenitor cells from individual chronic myeloid leukemia patients in immunodeficient mice. Leukemia 1999; 13: 618–628.
Eisterer W, Jiang X, Christ O, Glimm H, Lee K, Pang E et al. Different subsets of primary chronic myeloid leukemia stem cells engraft immunodeficient mice and produce a model of the human disease. Leukemia 2005; 27 January [E-pub ahead of print].
Eaves CJ, Eaves AC . Progenitor cell dynamics. In: Carella AM, Daley GQ, Eaves CJ, Goldman JM, Hehlmann R (eds). Chronic Myeloid Leukemia: Biology and Treatment. London: Martin Dunitz, 2001, pp 73–100.
Hoppin EC, Lewis JP . Polycythemia rubra vera progressing to Ph1-positive chronic myelogenous leukemia. Ann Intern Med 1975; 83: 820–823.
Lozzio CB, Lozzio BB . Human chronic myelogenous leukemia cell line with positive Philadelphia chromosome. Blood 1975; 45: 321–334.
Collins SJ, Groudine MT . Rearrangement and amplification of c-abl sequences in the human chronic myelogenous leukemia cell line K-562. Proc Natl Acad Sci USA 1983; 80: 4813–4817.
Andersson LC, Jokinen M, Gahmberg CG . Induction of erythroid differentiation in the human leukaemia cell line K562. Nature 1979; 278: 364–365.
Neumann F, Herold C, Hildebrandt B, Kobbe G, Aivado M, Rong A et al. Quantitative real-time reverse-transcription polymerase chain reaction for diagnosis of BCR-ABL positive leukemias and molecular monitoring following allogeneic stem cell transplantation. Eur J Haematol 2003; 70: 1–10.
Moravcova J, Zmekova V, Klamova H, Voglova J, Faber E, Michalova K et al. Differences and similarities in kinetics of BCR-ABL transcript levels in CML patients treated with imatinib mesylate for chronic or accelerated disease phase. Leukemia Res 2004; 28: 415–419.
Acknowledgements
We thank the staff of the Stem Cell Assay Service and the Flow Cytometry Facility of the Terry Fox Laboratory for initial cell processing and sorting, Dianne Reid for technical assistance, J Griffin (Dana Farber Cancer Institute, Boston, MA, USA) for the BCR-ABL plasmid, K Humphries and P Lansdorp (both from the Terry Fox Laboratory) for the MIG vector and antibodies, and StemCell (Vancouver, BC, Canada), Novartis (Basel, Switzerland), Cangene (Mississauga, ON, Canada) and Immunex (Seattle, WA, USA) for gifts of recombinant growth factors and other reagents. This work was supported by grants from the Cancer Research Society and the Leukemia Research Fund of Canada (XJ), the National Cancer Institute of Canada (with funds from the Canadian Cancer Society) and Genome BC (AE and CE). Y Chalandon was supported by a Terwindt Foundation Fellowship and O Christ by a German Research Foundation Fellowship.
Author information
Authors and Affiliations
Corresponding author
Additional information
Supplementary Information
Supplementary Information accompanies the paper on the Leukemia website (http://www.nature.com/leu).
Supplementary information
Rights and permissions
About this article
Cite this article
Chalandon, Y., Jiang, X., Christ, O. et al. BCR-ABL-transduced human cord blood cells produce abnormal populations in immunodeficient mice. Leukemia 19, 442–448 (2005). https://doi.org/10.1038/sj.leu.2403650
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2403650
Keywords
This article is cited by
-
Modeling BCR-ABL and MLL-AF9 leukemia in a human bone marrow-like scaffold-based xenograft model
Leukemia (2016)
-
Dominant-negative Ikaros cooperates with BCR-ABL1 to induce human acute myeloid leukemia in xenografts
Leukemia (2015)
-
Modeling chronic myeloid leukemia in immunodeficient mice reveals expansion of aberrant mast cells and accumulation of pre-B cells
Blood Cancer Journal (2014)
-
Long-term deregulated human hematopoiesis in goats transplanted in utero with BCR-ABL-transduced lin−CD34+ cord blood cells
Cell Research (2013)
-
Differential expression of the BCR gene in sequential stages of murine hematopoietic hierarchy
Leukemia (2011)